Multinational drug makers seem hell bent upon forcing the government to alter the patent regulations in their favour.

GlaxoSmithKline (GSK) announced that the Commercial Court in Dublin, Ireland, ruled in patent litigation regarding GSK's product Seretide, an inhaled respiratory treatment for asthma and COPD.

Introducing highly expensive patented drugs that show little or no improvement over existing ones -- or attempts to evergreen patents -- is getting tougher for multinationals.

In two different verdicts, the India's Patent Office rejected patent applications of two big pharma companies for two different products in the country. The rejected applications are for Caduet, a therapeutic combination of amlodipine and atorvastatin from Pfizer Ltd and another application for a rosiglitazone salt from GlaxoSmithKline.